Categories Earnings, Health Care

MannKind (NASDAQ: MNKD): Q3 2019 Earnings Snapshot

— MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected.

— The results were driven by increased total revenues from higher Afrezza commercial demand and from the licensing and research agreements with United Therapeutics.

Earnings Update by AlphaStreet

— Net revenues soared by 227% to $14.6 million versus $15.08 million expected.

— Afrezza net revenue jumped by 46% primarily driven by higher product demand, including the first shipment to Brazil, a more favorable mix of Afrezza cartridges and price.

— Collaborations and services revenue surged to $8.19 million from $82,000 last year, primarily driven by the license agreement with United Therapeutics, which began in the fourth quarter of 2018.

— Research and development (R&D) expense decreased by 23% year-over-year, primarily attributable to a decline in clinical trial spending.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Lennar (LEN) believes that despite near-term challenges, the long-term prospects for housing remain strong

Shares of Lennar Corporation (NYSE: LEN) were down 3% on Monday. The stock has dropped 36% year-to-date and 25% over the past 12 months. The homebuilder delivered mixed results for

KB Home (KBH): What did and did not work for the homebuilder in the third quarter

Shares of KB Home (NYSE: KBH) were up slightly on Friday. The stock has dropped 40% year-to-date and 35% over the past 12 months. The company delivered mixed results for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top